Samrat Pharmachem Ltd

Samrat Pharmachem Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Aug 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Samrat Pharmachem Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 August 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock's current position as of 23 August 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 August 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 12 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

The 50-day moving average has crossed above the 200-day moving average for Samrat Pharmachem Ltd, signalling a golden cross on 6 Aug 2026. Yet, the stock declined 0.27% on the day the cross formed, while monthly technical indicators remain mixed. This divergence between the moving averages and other signals calls for a detailed examination of the signal's reliability.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 June 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trend, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Samrat Pharmachem Limited reported a disastrous fourth quarter for FY2026, posting a net loss of ₹2.04 crores compared to a loss of ₹0.40 crores in the same quarter last year—a staggering deterioration of 410.00%. The micro-cap pharmaceutical chemicals manufacturer, with a market capitalisation of ₹65.00 crores, saw its stock plummet 15.63% to ₹210.00 on June 01, 2026, as investors reacted to the alarming financial performance that marked the company's worst quarterly showing in recent history.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 May 2026, providing investors with the latest insights into its performance and prospects.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook.

For the fifth consecutive session, Samrat Pharmachem Ltd closed lower, hitting a fresh 52-week low of Rs 194.4 on 30 Mar 2026. This decline comes amid a broader market that has shown some resilience, underscoring the stock's persistent underperformance.